Get the Daily Brief
Latest Biotech News
Oral GLP-1s heat up: Structure posts 'injectable-like' Phase 2 win
Structure Therapeutics reported Phase 2 data showing its oral GLP-1 candidate aleniglipron achieved up to 16% placebo‑adjusted weight loss at 44 weeks, positioning the pill as a potential oral...
Masked ADC shows activity in CRC... Investors take notice
CytomX updated clinical data for its conditionally activated (masked) EpCAM-targeting ADC, Varsetatug masetecan (Varseta‑M), reporting objective response rates of about 32% at a 10 mg/kg dose in...
Astellas walks away: $1.6B CytomX pact ends
Astellas Pharma terminated its multi‑target collaboration with CytomX that originally carried up to $1.6–$1.7 billion in milestones. The partnership—launched in 2020 to apply CytomX’s Probody...
Metapipeline‑DNA standardizes sequencing: automated genomics at scale
A team from Sanford Burnham Prebys and UCLA released metapipeline‑DNA, a Nextflow‑based automated pipeline for germline and somatic genomics that standardizes and scales DNA sequencing analysis...
AlphaFold expands to complexes: millions of protein interactions added
EMBL‑EBI, DeepMind, NVIDIA and collaborators released a massive expansion of AI‑predicted protein complex structures to the AlphaFold Database, providing millions of models for multi‑protein...
PerturbAI releases 8M‑cell CRISPR atlas—startup emerges from stealth
PerturbAI announced the public release of an in vivo Perturb‑seq CRISPR atlas mapping gene function across 8 million brain cells and emerged from stealth with undisclosed pre‑seed funding. The...
FDA clears Myriad MyChoice as Zejula companion: ovarian CDx approved
Myriad Genetics received FDA approval for its MyChoice CDx test as a companion diagnostic to identify homologous recombination deficiency (HRD) and BRCA mutations in patients eligible for GSK’s...
FDA rejects Aldeyra again: third CRL for reproxalap
The FDA issued a third complete response letter to Aldeyra Therapeutics for reproxalap, the company’s dry eye disease candidate, citing inconsistent and insufficient evidence of efficacy across...
NIH funding hold lifted: grants and hiring to resume
The White House Office of Management and Budget has released a hold on NIH apportionments, allowing the National Institutes of Health to begin spending its 2026 research budget and issuing new...
Federal court halts vaccine schedule overhaul, ACIP appointments stayed
A federal judge issued a preliminary stay blocking major elements of Health and Human Services Secretary Robert F. Kennedy Jr.’s overhaul of U.S. childhood vaccine policy, including a January memo...
Oral GLP‑1 pill posts strong Phase 2 weight loss – 16% at 44 weeks
Structure Therapeutics reported Phase 2 data showing its oral GLP‑1 candidate aleniglipron produced up to a 16% placebo‑adjusted weight reduction at 44 weeks, positioning the drug as a...
Roche and Nvidia strike deal: building pharma’s largest AI 'factory'
Roche signed a strategic partnership with Nvidia to build an expansive AI computing ecosystem aimed at accelerating drug discovery, diagnostics development, and internal R&D workflows. The plan...
Manufacturing push: ARPA‑H funds digital gene‑therapy platform; AutoCell automation advances
Public and private actors are investing in manufacturing solutions to unlock scalable gene and cell therapy production. ARPA‑H awarded BioCurie up to $9.3 million to build an AI‑driven,...
Astellas ends CytomX pact as CytomX posts encouraging CRC ADC data
Astellas walked away from its multi‑year collaboration with CytomX, exiting a partnership that originally carried up to $1.6–$1.7 billion in potential milestones. The split follows shifting...
PerturbAI publishes 8M‑cell in vivo CRISPR atlas and exits stealth
PerturbAI emerged from stealth while releasing a publicly accessible in vivo CRISPR perturbation atlas mapping gene function across 8 million brain cells. The dataset, generated using the...
Lipid innovations sharpen tissue targeting and immune tuning for LNPs
Two independent advances in lipid nanoparticle design promise to improve mRNA and gene‑therapy delivery by tuning tissue tropism and immune cell metabolism. Researchers described a class of...
In vivo base editing reverses neurodevelopmental disorder in preclinical model
Researchers reported that in vivo base editing corrected a pathogenic mutation and reversed disease phenotypes in a preclinical model of a neurodevelopmental disorder. The study demonstrates...
R1 Therapeutics raises $77.5M to advance AP‑306 for hyperphosphatemia in CKD
R1 Therapeutics launched with a $77.5 million Series A to develop AP‑306, an oral pan‑phosphate transporter inhibitor targeting hyperphosphatemia in chronic kidney disease and dialysis patients....
Oral GLP-1 pill rivals injectables: Structure posts 44‑week, phase‑2 win
Structure Therapeutics reported Phase 2 results showing its oral GLP‑1 candidate aleniglipron produced substantial, sustained weight loss in a 44‑week study. The company said participants on...
Federal judge freezes ACIP overhaul: vaccine schedule, appointments stayed
A federal judge issued a stay pausing major elements of Health and Human Services Secretary Robert F. Kennedy Jr.'s overhaul of the Advisory Committee on Immunization Practices (ACIP) and the...